Horm Metab Res 2019; 51(01): 69-75
DOI: 10.1055/a-0765-9078
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer

Jan Benedikt Groener
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Debora Gelen
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Carolin Mogler
2  Department of Pathology, Technical University of Munich, Munich, Germany
,
Esther Herpel
3  Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
4  Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
,
Csaba Toth
3  Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany
4  Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany
,
Zoltan Kender
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Marco Peichl
5  Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
,
Sabine Haufe
5  Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
,
Uwe Haberkorn
5  Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
6  Clinical Cooperation Unit Nuclear Medicine, Deutsches Krebsforschungszentrum, Heidelberg, Germany
,
Alba Sulaj
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Johanna Zemva
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Stefan Kopf
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Peter Paul Nawroth
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Maik Brune
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
,
Gottfried Rudofsky
1  Department of Endocrinology and Clinical Chemistry, Heidelberg University Hospital, Heidelberg, Germany
7  Department of Endocrinology, Cantonal Hospital Olten, Olten, Switzerland
› Author Affiliations
Further Information

Publication History

received 22 August 2018

accepted 11 October 2018

Publication Date:
05 November 2018 (eFirst)

Abstract

Radioiodine refractoriness in differentiated thyroid cancer remains an unsolved therapeutic problem. Response to retinoids might depend on specific genetic markers. In this retrospective analysis, associations between BRAF V600E and clinical outcomes after redifferentiation with retinoic acid (RA) and radioiodine therapy (RIT) were investigated. Thirteen patients with radioiodine-refractory (RAI-R) papillary thyroid cancer (PTC) were treated with 13-cis-RA followed by iodine-131 treatment at the Department of Endocrinology, Heidelberg University Hospital, Heidelberg, Germany. DNA sequencing was performed in formalin-fixed paraffin-embedded tissue. Clinical outcome parameters were tumor size, thyroglobulin, and radioiodine uptake in correlation to mutational status. Differences of each parameter were compared before and after RA/RIT. Initial response showed no difference in patients with BRAF V600E compared to patients with wild type. However, after a median follow-up of 2 and a half years, 2 out of 3 patients with BRAF V600E showed response compared to 5 out of 9 with wild type under consideration of all 3 parameters. In this small cohort, more RAI-R PTC patients with BRAF V600E receiving redifferentiation therapy showed response. Verification in a larger study population analyzing mutational status in patients with RAI-R PTC might be helpful to identify patients where redifferentiation therapy might lead to an improved outcome.

* These 2 authors contributed equally to this publication and share first authorship


#  These 2 authors contributed equally to this publication and share senior authorship